

Our Purpose, Values and business model

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.

Our business model

We are a global pharmaceutical business with a science-led and patient-focused value proposition committed to excellence in the research, development, manufacturing and commercialisation of prescription medicines. We are also committed to operating sustainably, in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet. We invest resources to create financial and non-financial value that benefit patients, society, the planet and our business.

Our Purpose

We push the boundaries of science to deliver life changing medicines.

Our Values

- > We follow the science.
- > We put patients first.
- > We play to win.
- > We do the right thing.
- > We are entrepreneurial.

Requirements for success and how we performed in 2023

Ability to acquire, retain and develop a talented and diverse workforce.

50.1%

of our senior middle management roles and above are filled by women

A leadership position in science that enables us to deliver life-changing medicines.

\$10.9bn

invested in our science in 2023

Understanding the issues that are most important to our many and varied stakeholders.

>199,000

healthcare practitioner enquiries responded to

Effective collaborations that supplement and strengthen our pipeline and our efforts to achieve scientific leadership.

>1,000

collaborations worldwide

Global commercial presence and skills that ensure our medicines are available to patients when needed.

>125

countries where we sell our products

Patent protection for our intellectual property for a reasonable period of time to prevent our new medicines being copied.

>90

countries where we obtained patent protection

A supply of high-quality medicines, whether from our own operations or from suppliers.

\$22.2bn

spent with suppliers

Financial strength, including access to financing and ability to bear the financial risk of investing in the life-cycle of a medicine.

\$10.3bn

net cash flow from operating activities

Helping patients

>116m¹

Our main therapy area medicines impact more than 116 million patient lives annually.

¹ The patient numbers reached for AstraZeneca medicines is an estimation of the average number of patients on our medicines in a given year. The calculation is based upon the volume that we manufacture globally, converted using the number of days of therapy (DoT) and the average patient compliance with their treatment. If a patient is treated by more than one AstraZeneca product they are double-counted.